目的:本研究試圖導入決策輔助系統(decision support system, DSS)協助藥品採購量控管,收集各項數據以分析評估是否改善履約管理問題。方法:建置DSS並定義各燈號之閾值,導入DSS後統計自2021年9月27日系統啟用之初至2022年6月27日之資料,比較期初至期末的亮燈品項數變化情形,以及導入系統前後卡單品項數之差異。結果:2022年各燈號的亮燈周平均比率皆低於2021年,尤其亮紅燈及亮黃燈的下降具有統計上的差異。卡單品項數由導入前每月平均51.3±15.1項有意義地降至導入後1.5±2.1項。結論:以DSS管控藥品採購量至今成效顯著,期待日後藉由DSS更精確的掌控個別藥物、減低人工作業的時間及錯誤,朝向更優化的藥物履約管理邁進。
Objective: The current study aimed to introduce a decision support system (DSS) for drug purchase volume control and collected data to assess if the implementation improved the performance of drug contract management. Methods: Established the DSS and defined the thresholds of warning notices/ lights. We collected data from September 27, 2021 to June 27, 2022, and compared the changes in warning notices/lights between the initial and the end stages and the number of undelivered items before and after the system introduction. Results: On average, the warning notices/lights rates were lower in 2022 than in 2021, and the number of red and yellow lights decreased significantly. The average number of undelivered items (exceeding the budget limit) was 51.3 ± 15.1 before DDS implementation and was lowered to 1.5 ± 2.1 after. Conclusion: The effectiveness of DSS for drug purchase management was remarkable. We anticipate a future DDS that can reduce human operation time and errors and control individual drug contracts more precisely. As such, we can proceed to a better optimize drug contract management.